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Abstract 
Neuroblastoma is the most common and deadly cancer in the first year of life. Children 
with high-risk neuroblastoma have a very poor prognosis, despite heavy multimodal 
treatment, with less than 50% of 5 years of overall survival. Unfortunately, between 50-
60% of high-risk neuroblastoma patients will eventually suffer a relapse with a survival 
rate of less than 10%. For this reason, a better understanding of the interplay between 
genetic abnormalities within the nervous system context is necessary to improve patient 
stratification or aid therapeutic strategies that can ultimately lead to increased patient 
survival. 
In order to find molecular profiles that predispose to development of high-risk 
neuroblastoma or contribute to the relapse, metastatic or non-responsive status of the 
tumor, we performed comprehensive molecular characterization of neuroblastoma 
tumors and cell lines by SNP-microarrays and next generation sequencing techniques 
in combination with functional exploration of novel recurrent somatic aberrations. 
Through our large-scale studies, we confirmed the genetic stability of neuroblastoma 
PDOXs over serial passaging, explored intra-tumoral heterogeneity of neuroblastoma 
and monitored a set of primary/relapsed neuroblastoma tumors, highlighting the 
recurrence of alterations of MAPK signaling, cell cycle progression and telomere 
activity pathways. Furthermore, we detected and investigated a recurrent structural 
alteration in LSAMP which appears to be a tumor suppressor gene in neuroblastoma. 
We also characterized a highly aggressive subgroup of neuroblastoma tumors, which 
presented a high-grade amplification of two loci at 12q, and our in vitro results indicated 
possible tumor inhibition routes through CDK4 and MDM2 inhibition. 
To conclude, genome-wide analyses with powerful techniques, such as next generation 
sequencing, are useful not only for research purposes but also as a clinical tool. 
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